The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females.
Yanxia ChenAubin MoutalEdita NavratilovaCaroline M KopruszinskiXu YueMegumi IkegamiMichele ChowIori KanazawaShreya Sai BellampalliJennifer Yanhua XieAmol PatwardhanKenner RiceHoward L FieldsArmen AkopianVolker NeugebauerDavid DodickRajesh KhannaFrank PorrecaPublished in: Science translational medicine (2021)
Pain is more prevalent in women for reasons that remain unclear. We have identified a mechanism of injury-free nociceptor sensitization and opioid-induced hyperalgesia (OIH) promoted by prolactin (PRL) in females. PRL signals through mutually inhibitory long (PRLR-L) and short (PRLR-S) receptor isoforms, and PRLR-S activation induces neuronal excitability. PRL and PRLR expression were higher in females. CRISPR-mediated editing of PRLR-L promoted nociceptor sensitization and allodynia in naïve, uninjured female mice that depended on circulating PRL. Opioids, but not trauma-induced nerve injury, decreased PRLR-L promoting OIH through activation of PRLR-S in female mice. Deletion of both PRLR-L and PRLR-S (total PRLR) prevented, whereas PRLR-L overexpression rescued established OIH selectively in females. Inhibition of circulating PRL with cabergoline, a dopamine D2 agonist, up-regulated PRLR-L and prevented OIH only in females. The PRLR-L isoform therefore confers protection against PRL-promoted pain in females. Limiting PRL/PRLR-S signaling pharmacologically or with gene therapies targeting the PRLR may be effective for reducing pain in a female-selective manner.